Concr is hiring Commercial Leader Leigh Pugh to join the panel in Oslo in July 2026.

[𝗠𝘂𝗹𝘁𝗶-𝗺𝗼𝗱𝗮𝗹 𝗱𝗮𝘁𝗮] + [𝗙𝗮𝗿𝗿𝗦𝗶𝗴𝗵𝘁® 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺] = "𝗪𝗵𝗮𝘁 𝗶𝗳?" 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗧𝘄𝗶𝗻 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our FarrSight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Debiopharm, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland, our solutions are trusted by researchers in industry, academia and healthcare. Concr’s investors include the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Parkwalk Advisors, Deep Science Ventures and SyndicateRoom. The company has also received a grant from Innovate UK to trial Concr’s technology for improving treatment decision-making in clinic. The company’s HQ is in London, England, with a wholly owned subsidiary in Brisbane, Australia.